Dr. Tong Zhang is the co-founder, CBO/CFO of VelaVigo. Prior to VelaVigo he was Chief Business Officer at Shanghai Genechem, Managing Director at C-Bridge Capital (CBC), a healthcare focused PE, responsible for sourcing, evaluation and execution of investment opportunities focusing on China market, as well as incubating and managing portfolio companies. Prior to CBC, Tong was head of Corporate BD at WuXi AppTec, responsible for strategic partnership and M&A, head of Business Development for MSD China and pan-regional BD lead at Merck & Co., head of Business Development at EKR Therapeutics, a VC-backed specialty pharmaceutical company in the US. Tong also had investment experience as a Director at ESP Equity Partners, and equity analyst covering the US pharmaceutical industry for Credit Suisse in New York. Tong worked as a consultant for ISO HealthCare Consulting (now part of the Monitor Group) and Defined Health, leading strategy consulting firms in the biopharmaceutical industry. Tong received his Ph.D. in Biology from Columbia University and a B.S. degree in Biology from Wuhan University in China. He also performed post-doctoral research at Sloan-Kettering Cancer Center in New York in the lab of Nobel Laureate Dr. James Rothman.